Glioblastoma (brain cancer) and LAT-1 program

Telix’s GBM program targets LAT-1 (L-type amino acid transporter 1) a membrane transport protein that is typically highly expressed in GBM. TLX101 is a novel approach that is readily able to pass through the blood-brain barrier, the normal protective barrier that prevents many potential drug candidates from entering the brain.

The mainstay of treatment for glioblastoma comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients.

Glioblastoma (GBM) worldwide

300,000

people were diagnosed with brain or central nervous system cancer globally in 2020

50%

of all brain tumours are GBM

12-15

months median overall survival from diagnosis

5%

5-year survival rate